Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅰ, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects

NCT06883695 is registered in ClinicalTrials.gov with Guangdong Hengrui Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT06883695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06883695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅰ, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects
Lead sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
April 8, 2025
Completion date
October 10, 2025
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis